Health Care/Hospital
Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program
SHANGHAI, Nov. 7, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that i...
2021-11-08 08:10
1858
PromarkerD significantly outperforms current standard of care tests in predicting future kidney function decline
* Study shows PromarkerD is significantly better than current standard of care tests eGFR and ACR for predicting future decline in kidney function in patients with type 2 diabetes * PromarkerD correctly identified 84% of patients with normal kidney function that went on to experience kidney f...
2021-11-05 20:37
1767
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases
MELBOURNE, Australia, Nov. 5, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the publication of two preclinical studie...
2021-11-05 14:57
1533
ASH 2021 | Ascentage Pharma to Release Latest Data from Two Studies of Its Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a Chinese Study Demonstrating Complete Response
SUZHOU, China, and ROCKVILLE, MD., Nov. 4, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that abstracts on six studies of the company's thr...
2021-11-05 09:05
3198
ASH 2021 | Ascentage Pharma to Present Three Studies of Olverembatinib (HQP1351), a Novel Drug Candidate for the Treatment of Drug-Resistant Leukemia, in Abstracts Including One Oral Report at ASH Annual Meeting
SUZHOU, China and ROCKVILLE, MD., Nov. 4, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that abstracts on three clinical trials of the c...
2021-11-05 08:43
2346
Lunit to Participate in RSNA 2021, Presenting its New AI Solutions for Digital Breast Tomosynthesis and Chest CT
SEOUL, South Korea, Nov. 4, 2021 /PRNewswire/ -- Lunit, a leading medical AI provider, will be returning to the 107th Radiological Society ofNorth America (RSNA) this year with its up-to-date, comprehensive AI solutions for chest and breast radiology. Along with its most mature products, the comp...
2021-11-04 23:00
1805
Gracell Biotechnologies to Present Preclinical Results of TruUCAR-enabled CD19/CD7 Dual-Directed Allogeneic CAR-T Cell Therapy (GC502) for B-Cell Malignancies at the 63rd ASH Annual Meeting
SUZHOU and SHANGHAI, China, and PALO ALTO, California, Nov. 4, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, toda...
2021-11-04 21:05
1764
I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma at ASH 2021
* Lemzoparlimab is a differentiated CD47 monoclonal antibody discovered by I-Mab and being developed in collaboration with AbbVie * Initial clinical results of lemzoparlimab in combination with rituximab in NHL will be presented at the ASH 2021 Annual Meeting * I-Mab to host a call for inves...
2021-11-04 21:00
1515
Volition Veterinary Presents Two Posters at the 2021 Veterinary Cancer Society Conference
* Positive data show Nu.Q® can be used to monitor for disease response and progression including remission monitoring in cancer bearing dogs. * Paves the way for second Nu.Q® Vet product launch planned for 2022. * A second abstract details the first use of Nu.Q® Capture, Volition's enrichmen...
2021-11-04 20:33
2894
Taizhou, China: Building a Famous Chinese Medical City with Efforts
TAIZHOU, China, Nov. 4, 2021 /PRNewswire/ -- Recently, the 12th China (Taizhou) International Medical Expo was held inChina Medical City in Taizhou, China. Starting from the needs of normalized prevention and control of the epidemic, this year's expo made an "online+on-site" integrated exhibition...
2021-11-04 20:16
1257
Medigate Accelerates Expansion to Meet Growing Demand in Asia-Pacific Region
Healthcare's IoT cybersecurity and clinical asset management leader names APAC Regional Director. BROOKLYN, N.Y., Nov. 4, 2021 /PRNewswire/ -- Medigate, Healthcare's Security and Clinical Asset Management leader, today announced its expansion into the Asia-Pacific (APAC) region. Capitalizing on ...
2021-11-04 20:15
1562
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases
MELBOURNE, Australia, Nov. 4, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the publication of two preclinical studie...
2021-11-04 19:30
1464
Medtecs to showcase PPE and technologies from Taiwan at MEDICA 2021
TAIPEI, Nov. 3, 2021 /PRNewswire/ -- It is now half-way through autumn and the COVID-19 pandemic still persists. The global death toll has reached over 5 million yet only 45.4% of the global population has received at least one dose of vaccine. To make matters worse, a new subvariant of the virus...
2021-11-04 09:56
1726
Gold Technology for Immune Response Cancer Therapy Licensed to OncoTEX
AUSTIN, Texas, Nov. 3, 2021 /PRNewswire/ -- OncoTEX Inc. (OncoTEX), a US oncology company and member of The iQ Group Global portfolio, is pleased to announce it has acquired a gold compound platform technology that induces the body's immune system to destroy cancer cells. The technology has been...
2021-11-03 22:00
1548
TransThera Receives Fast Track Designation from FDA for its Core Product TT-00420 to Treat Cholangiocarcinoma
NANJING, China, Nov. 3, 2021 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative small molecule drug therapies for oncology, inflammatory and cardiovascular diseases, announced that the U.S. Food and Drug...
2021-11-03 22:00
1543
Standigm Files PCT Patent Application of AI-driven Repurposed Drugs for Primary Mitochondrial Disease
SEOUL, South Korea, Nov. 3, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that the company had filed PCT ("Patent Cooperation Treaty") patent application covering AI-driven repurposed drugs for primary m...
2021-11-03 21:00
1547
I-Mab Announces Upcoming Participation at November Conferences
SHANGHAI and GAITHERSBURG, Md., Nov. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced its participation in the following conferences in Novemb...
2021-11-03 20:00
1386
BioKangtai's adenovirus vector COVID-19 vaccine obtained EUA in Indonesia
SHENZHEN, China, Nov. 3, 2021 /PRNewswire/ -- As reported by Indonesian National Agency of Drug and Food Control (BPOM), BPOM grants the Emergency Use Authorization (EUA) for COVID-19 Vaccine (ChAdOx1-S[recombinant])/KconecaVac manufactured by Shenzhen Kangtai Biological Products Co., Ltd. It is ...
2021-11-03 19:02
1609
Vazyme to Reveal Its Latest COVID-19 Testing Products and Solutions at MEDICA 2021
DÜSSELDORF, Germany, Nov. 3, 2021 /PRNewswire/ -- Chinese biotechnology company Nanjing Vazyme Biotech Co., Ltd (Vazyme) will exhibit its advanced COVID-19 testing products and solutions in Hall 3 Stand F 94 at MEDICA 2021, the world's leading trade fair for the medical sector, in Messe Düsseldor...
2021-11-03 15:00
1776
Chong Yoon Lim, CEO of Hanmi Science, announces addition of eWorldwide Group to Hanmi Science Consortium and invites other groups to join
LONDON, Nov. 3, 2021 /PRNewswire/ -- In his recent opening address to the G20, Italian Prime MinisterMario Draghi highlighted vaccine inequity, emphasizing the fact that only 3% of eligible people living in the world's poorest nations had received any form of COVID-19 vaccine, versus more than 70...
2021-11-03 12:28
1510
Week's Top Stories
Most Reposted
2024 Malaysia E-Commerce Product Selection Expo Attracts International Delegations
[Picked up by 311 media titles]
2024-12-02 12:06
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 298 media titles]
2024-11-28 17:24Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 286 media titles]
2024-11-29 20:33
Most Read
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
2024-11-29 20:33
8733
Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
2024-11-26 13:00
5188